Archive
1250 articles, sorted by publication time.
A randomized trial involving 185 people found that starting with personalized non-drug interventions and then introducing medications step by step according to a defined process can reduce psychiatric polypharmacy early in treatment; however, the difference was no longer significant by week 12, and the evidence remains insufficient to change long-term care standards.
As it seeks new funding, Ensoma is putting its sickle cell disease and oncology research on hold, betting on an in vivo hematopoietic stem cell therapy that has entered a Phase 1/2 trial; the pullback also makes EN-374’s early clinical data critical to whether the platform can continue.
The most extensive reform of clinical trial regulations in more than two decades creates fast-track pathways for low-risk research and certain amendments; the other side of the bargain is that public registration, results disclosure, and communication with participants are shifting from advocacy to legal obligations.
Of 285 synthetic designs, the research team validated 16 bacteriophages capable of infecting and killing E. coli; when used as a mixture, they also overcame resistance in laboratory evolution experiments that the prototype bacteriophage could not breach.
The new funding will support completion of dose escalation for STC-1010, expansion of the patient cohort, and preparations for the next candidate therapy; however, the existing clinical signals come from only a small number of patients, and the effects of chemotherapy itself cannot yet be ruled out.
The oral nucleotide analog has entered a Phase 1 trial in Belgium, initially assessing safety and pharmacokinetics in healthy volunteers; whether it can treat chronic hepatitis E will remain unanswered until trials in patients are conducted.
The clinical-stage company plans a $400 million private placement with the RAIN Foundation and retains the right to raise another $400 million; the transaction could substantially dilute existing shareholders, while the concentration of both funds and tokens within the same ecosystem puts drug development, corporate governance, and asset liquidity in the spotlight.
From market intelligence and physician marketing to supply chain and legal affairs, Veradermics is building the commercial framework for extended-release oral minoxidil. However, the pivotal confirmatory trial has yet to report results, and the hiring activity signals launch preparation—not that the regulatory outcome is already assured.
A single intra-articular injection failed to improve pain and knee function, with both primary measures similar to placebo; Kolon TissueGene will await results from another phase 3 trial before deciding TG-C’s future.
The new funding will support the early clinical development of IDP-001. Whether this antibody-drug conjugate, which recognizes both EGFR and a neighboring tumor antigen, can broaden the therapeutic window in squamous cell carcinomas will first depend on safety and dose testing.
A total of 15 people have received sasineprocel in the early-stage ASPIRO trial; the latest two cohorts are the first to use a cryopreserved formulation that can be thawed upon arrival and injected immediately, marking a major step in manufacturing and clinical distribution rather than a definitive conclusion on efficacy.
Amivantamab recorded a 42% tumor response rate in patients whose previous treatments had failed, offering a new path for advanced head and neck cancer with limited treatment options; however, the evidence still comes from an early-stage single-arm trial, and Priority Review does not mean approval.